期刊文献+

逆向性房室折返性心动过速临床诊治24例 被引量:1

下载PDF
导出
摘要 目的:探讨逆向性房室折返性心动过速患者临床诊治特点。方法:收集逆向性房室折返性心动过速患者24例,在一般治疗基础上,选用5%葡萄糖20ml加普罗帕酮70mg缓慢静脉推注,转复为窦性心律后即停止注射。若无效可于20min后再给与普罗帕酮35mg缓慢静脉推注,可反复应用,总量不超过210mg。应用普罗帕酮若无效,可换用5%葡萄糖20ml加胺碘酮150mg缓慢静脉推注,共推注约10min。5例出现持续性低血压或伴晕厥的患者以及经药物治疗无效的患者采用同步直流电复律。结果:2例经物理方法治疗后有效,13例使用普罗帕酮1次,2例使用普罗帕酮2次,1例使用普罗帕酮2次和胺碘酮1次,6例行同步直流电复律后恢复为窦性心律。结论:普罗帕酮对逆向性房室折返性心动过速是很有效的。治疗中,一旦出现血液动力学障碍或药物治疗无效时,应采取同步直流电复律。
出处 《陕西医学杂志》 CAS 2014年第3期325-326,共2页 Shaanxi Medical Journal
  • 相关文献

参考文献4

二级参考文献21

  • 1胡大一,丁燕生,马长生,李毅刚,李宜富,王家宁,王乐信,汪丽蕙.561例快速心律失常射频消蚀经验[J].中华心血管病杂志,1994,22(1):14-15. 被引量:84
  • 2何胜,邱全煌,姜椿法,周南南.静脉注射胺碘酮或普罗帕酮治疗阵发性室上性心动过速的对比研究[J].岭南急诊医学杂志,2006,11(3):167-168. 被引量:7
  • 3潘三葱,秦中胜,张卫玲,韩麦丰,王丽.胺碘酮治疗急性心肌梗死后快速心律失常的临床观察[J].疑难病杂志,2006,5(6):436-437. 被引量:11
  • 4中华心血管病杂志编辑委员会.全国快速心律失常的非药物治疗专题研讨会纪要[J].中华心血管病杂志,1993,21:95-95.
  • 5Lafuente C,Mouly S,Longas-Tejero MA,et al.Antiarrhythmics for maintaining sinus rhythm after cardioversion of paroxysmal supraventricular tachycardia[J].Cochrane Database Syst Rev,2012,5:CD005049.
  • 6李春玲.胺碘酮与普罗帕酮治疗阵发性室上性心动过速的疗效观察[J].中外健康文摘,2010,7(19):75-75.
  • 7Garcia A.Adverse effects of propafenone after long-term therapy with the addition of citalopram[J].Am J Geriatr Pharmacother,2008,6(2):96- 99.
  • 8Reingardene DI,Zhilene VI.Dermatological adverse reactions of amiodarone [J].Kardiologiia,2005,45(4):27-30.
  • 9Kuck HK, Friday KJ, Kunze KP,et al. Sites of conduction block in access ory atr ioventricular pathway-basis for concealed accessory pathway [J]. Circulation, 1990, 82 (2) :407.
  • 10Jackman WM, Friday K J, Schlerlag BJ, et al. Direct endo- cardial recording from a n accessory atrioventricular path- way:localization of site of block, effect of ant iarrhythmic drugs and attempt at nonsurgical ablation[J]. Circulation, 1983,68(5) :905.

共引文献58

同被引文献19

  • 1古丽巴哈尔.阿不力米提,张明.妊娠合并阵发性室上性心动过速的处理[J].心血管康复医学杂志,2006,15(4):377-378. 被引量:1
  • 2Savelieva I, Graydon R, Camm AJ. Pharmacological cardio- version of atrial fibrillation with vernakalant., evidence in sup- port of the ESC Guidelines [Jq. Europace, 2014, 16 (2) 162 - 173.
  • 3Conde D, Costabel JP, Aragon M, et al. Propafenone versus vernakalant for conversion of recent - onset atrial fibrillation [J]. Cardiovase Ther, 2013, 31 (6): 377-380.
  • 4Heldal M, Atar D. Pharmacological conversion of recent- on- set atrial fibrillation: A systematic review [J]. Scand Cardio- vase J, 2013, 47 (1): 2-10.
  • 5Rostagno C. Atrial fibrillation in patients undergoing surgical revascularization: an update on pharmacologic prophylaxis [J]. Cardiovasc Hematol Agents Med Chem, 2012, 10 (4) 325 - 338.
  • 6Rajagopalan B, Curtis AB. Contemporary approach to electri- cal and pharmacological cardioversion of atrial fibrillation [J]. Postgrad Med, 2012 124 (6): 26-35.
  • 7Carom J. Antiarrhythmic drugs for the maintenance of sinus rhythm risks and benefits [J]. Int J Cardiol, 2012 155 (3) : 362 - 371.
  • 8McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal [J]. Pharmacoeconomics, 2012, 30 (1): 35-46.
  • 9Cohen M, Boiangiu C. The management of patients with atrial fibrillation and dronedarone's place in therapy [J]. Adv Ther, 20{1, 28 (12) z 1059-1077.
  • 10Balla I, Petrela E, Kondili A. Pharmacological conversion of recent atrial fibrillation: a randomized, placebo - controlled study of three antiarrhythmie drugs [J]. Anadolu Kardiyol Derg, 2011, 11 (7): 600-606.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部